Literature DB >> 12478322

Invasive Aspergillosis in Italian AIDS patients.

M Libanore1, E Prini, M Mazzetti, E Barchi, E Raise, F M Gritti, L Bonazzi, F Ghinelli.   

Abstract

BACKGROUND: We studied the prevalence, epidemiological features, symptoms, diagnosis, treatment and outcome of invasive aspergillosis in AIDS patients in Italy. PATIENTS AND METHODS: All patients affected by both aspergillosis and AIDS hospitalized between January 1986 and April 1997 (before highly-active antiretroviral therapy, HAART) in four Italian Department of Infectious Disease. Patients were included in the study only if culture, cytology or histology showed firm evidence of Aspergillus infection. Invasive aspergillosis was defined as the presence of characteristic, closely septate hyphae with repeated acute angle branching in either biopsy materials or percutaneous aspirates from tissues other than the lung. Hyphae were identified using hematoxylin-eosin and methenamine silver stain.
RESULTS: During the study, 54 out of 2,614 patients admitted with AIDS showed aspergillosis (2.1%). The disease usually occurred in patients with < 50 CD4 cells/mm(3). Aspergillosis was associated with neutropenia and steroid treatment. Nonspecific symptoms were frequently encountered. Fever and cough were both present in > 70% of the cases of pulmonary aspergillosis. Biopsy specimens were analyzed for definitive diagnosis. Invasive aspergillosis is usually treated with amphotericin B, but in 90% of the cases this did not prevent death.
CONCLUSION: In AIDS patients with neutropenia and long-term steroid therapy, it is important to consider invasive aspergillosis in the differential diagnosis of opportunistic infections.

Entities:  

Mesh:

Year:  2002        PMID: 12478322     DOI: 10.1007/s15010-002-2033-1

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  6 in total

Review 1.  Cavitary pulmonary disease.

Authors:  L Beth Gadkowski; Jason E Stout
Journal:  Clin Microbiol Rev       Date:  2008-04       Impact factor: 26.132

Review 2.  Primary invasive aspergillosis of the digestive tract: report of two cases and review of the literature.

Authors:  P Eggimann; J-C Chevrolet; M Starobinski; P Majno; M Totsch; B Chapuis; D Pittet
Journal:  Infection       Date:  2006-12       Impact factor: 3.553

Review 3.  Clinical and economic burden of invasive fungal diseases in Europe: focus on pre-emptive and empirical treatment of Aspergillus and Candida species.

Authors:  L Drgona; A Khachatryan; J Stephens; C Charbonneau; M Kantecki; S Haider; R Barnes
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-09-12       Impact factor: 3.267

4.  Pulmonary aspergillosis as opportunistic mycoses in a cohort of human immunodeficiency virus-infected patients: Report from a tertiary care hospital in North India.

Authors:  Ravinder Kaur; Bhanu Mehra; Megh Singh Dhakad; Ritu Goyal; Richa Dewan
Journal:  Int J Health Sci (Qassim)       Date:  2017 Apr-Jun

5.  The Emergence of Rare Clinical Aspergillus Species in Qatar: Molecular Characterization and Antifungal Susceptibility Profiles.

Authors:  Husam Salah; Michaela Lackner; Jos Houbraken; Bart Theelen; Cornelia Lass-Flörl; Teun Boekhout; Muna Almaslamani; Saad J Taj-Aldeen
Journal:  Front Microbiol       Date:  2019-07-30       Impact factor: 5.640

6.  Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis.

Authors:  David W Denning; Kieren A Marr; Wendi M Lau; David P Facklam; Voravit Ratanatharathorn; Cornelia Becker; Andrew J Ullmann; Nita L Seibel; Patricia M Flynn; Jo-Anne H van Burik; Donald N Buell; Thomas F Patterson
Journal:  J Infect       Date:  2006-05-06       Impact factor: 6.072

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.